NCT05981118
Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)
Enrolling by Invitation
PHASE2Ages 18+InterventionalHealth servicesWake Forest University Health SciencesInvestigator-initiated
~40 participants
Updated 2026-08-04 on ClinicalTrials.gov
What's tested:Betamethasone dipropionate 0.05%Tapinarof
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Examine the degree of Post-inflammatory pigment alteration (PIPA) in both intervention Arms
Measured over Baseline to week 1
+2 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesNorth Carolina1
Study leadership
- Steven R Feldman, MD, PhD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Examine the degree of Post-inflammatory pigment alteration (PIPA) in both intervention ArmsBaseline to week 1
Details regarding the area of pigmentation changes, intensity of hyper- or hypopigmentation, erythema, burning, and dryness will be assessed. PIPA will be assessed using the Taylor Pigmentation Scale
- Examine the degree of Post-inflammatory pigment alteration (PIPA) in both intervention ArmsWeek 1 to week 4
Details regarding the area of pigmentation changes, intensity of hyper- or hypopigmentation, erythema, burning, and dryness will be assessed. PIPA will be assessed using the Taylor Pigmentation Scale
- Examine the degree of Post-inflammatory pigment alteration (PIPA) in both intervention ArmsWeek 4 to week 12
Details regarding the area of pigmentation changes, intensity of hyper- or hypopigmentation, erythema, burning, and dryness will be assessed. PIPA will be assessed using the Taylor Pigmentation Scale